K Number
K972530

Validate with FDA (Live)

Date Cleared
1997-10-01

(86 days)

Product Code
Regulation Number
880.5090
Age Range
All
Reference & Predicate Devices
N/A
Predicate For
N/A
AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticPediatricDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
Intended Use

ConvaTec Odor Control Wound Dressing is indicated for the management of malodorous acute and chronic wounds such as pressure ulcers, leg ulcers, and diabetic ulcers. It may be used as a primary dressing for superficial wounds or with deeper wounds as a secondary dressing.

Device Description

ConvaTec Odor Control Wound Dressing is a sterile, non-adhesive dressing with an absorbent wound contact laver, a water-resistant film layer, an activated charcoal central pad, a non-woven absorbent pad layer and a smooth water- resistant outer film layer.

AI/ML Overview

This document does not contain information about acceptance criteria or a study proving that a device meets acceptance criteria. The document is a 510(k) premarket notification for a wound dressing, demonstrating substantial equivalence to a predicate device. It includes:

  • Device Description: ConvaTec Odor Control Wound Dressing, a sterile, non-adhesive dressing with multiple layers and an activated charcoal pad.
  • Intended Use: Management of malodorous acute and chronic wounds (pressure ulcers, diabetic ulcers), as a primary or secondary dressing.
  • Contraindications: Individuals with known sensitivity to the dressing or its components.
  • Substantial Equivalence Claim: To Hollister Odor-Absorbent Dressing, based on similar intended uses, characteristics, construction, and central carbon layer.
  • Bench Testing: Comparative bench testing was conducted on both devices.
  • Biocompatibility Testing: ConvaTec Odor Control Wound Dressing was subjected to ISO 10993 Part I demonstrating it is nonsensitizing, non-toxic, non-hemolytic, and a negligible irritant.
  • FDA Response: The FDA reviewed the 510(k) and determined the device is substantially equivalent, allowing it to be marketed subject to general controls and specific labeling limitations (not for third-degree burns, no claims of accelerating healing, not a long-term/permanent dressing, not a treatment/cure).

There is no mention of specific acceptance criteria or performance metrics, nor a study designed to demonstrate the device meets such criteria. The "study" mentioned is "Comparative bench testing" and "biocompatibility testing," which are used to establish substantial equivalence and safety, not to meet pre-defined performance acceptance criteria.

{0}------------------------------------------------

OCT - 1 1997

ITEM 8: SUMMARY OF SAFETY AND EFFECTIVENESS

The purpose of this 510(k) Premarket Notification is to request clearance to market ConvaTec Odor Control Wound Dressing.

ConvaTec Odor Control Wound Dressing is a sterile, non-adhesive dressing with an absorbent wound contact laver, a water-resistant film layer, an activated charcoal central pad, a non-woven absorbent pad layer and a smooth water- resistant outer film layer.

ConvaTec Odor Control Wound Dressing is indicated for the management of malodorous acute and chronic wounds such as pressure ulcers and diabetic ulcers. It may be used as a primary dressing for superficial wounds or with deeper wounds as a secondary dressing.

ConvaTec Odor Control Wound Dressing is contraindicated for use on individuals with known sensitivity to the dressing or its components.

ConvaTec Odor Control Wound Dressing is substantially equivalent to Hollister Odor-Absorbent Dressing. Both dressings have essentially the same intended uses and characteristics. ConvaTec Odor Control Wound Dressing is similar in construction and design to Hollister's Odor Absorbent Dressing whereby both dressings are sterile, non-adhesive with a multilayer construction containing a central carbon layer.

Comparative bench testing was conducted on Hollister Odor-Absorbent Dressing and ConvaTec Odor Control Wound Dressing.

ConvaTec Odor Control Wound Dressing has been subjected to biocompatibility testing utilizing the ISO 10993 Part I "Biological Evaluation of Medical Devices" with FDA modified matrix (Guidance effective July 1, 1995), The results of this testing demonstrate that ConvaTec Odor Control Wound Dressing is considered to be nonsensitizing, non-toxic, non-hemolytic and a negligible irritant.

ConvaTec, A Division of E.R. Squibb & Sons, Inc.

{1}------------------------------------------------

Image /page/1/Picture/1 description: The image shows the seal of the Department of Health & Human Services - USA. The seal is circular and contains the words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. In the center of the seal is an abstract image of a human figure.

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20856

Ms. Adrienne McNally . Manager, Regulatory Affairs ConvaTec. Inc. PO Box 5254 Princeton, New Jersey 08543-5254

OCT - 1 1997

Re: K972530 ConvaTec Odor Control Wound Dressing Regulatory Class: Unclassified Product Code: KMF Dated: July 3, 1997 Received: July 7, 1997

Dear Ms. McNally:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act). You may, therefore, market your device subject to the general controls provisions of the Federal Food, Drug, and Cosmetic Act (Act) and the following limitations:

  1. This device may not be labeled for use on third degree burns.

  2. This device may not be labeled as having any accelerating effect on the rate of wound healing or epithelization.

  3. This device may not be labeled as a long-term, permanent, or no-change dressing, or as an artificial (synthetic) skin.

  4. This device may not be labeled as a treatment or a cure for any type of wound.

The labeling claims listed above would be considered a major modification in the intended use of the device and would require a premarket notification submission (21 CFR 807.81).

{2}------------------------------------------------

Page 2 - Ms. Adrienne McNally

The general controls provisions of the Act include requirements for annual registration. listing of devices, good manufacturing practices, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval) it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations (CFR), Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Good Manufacturing Practices (GMP) for Medical Devices: General GMP regulation (21 CFR Part 820) and that, through periodic GMP inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of ... Compliance at (301) 594-4595. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or 301-443-6597 or at its internet address http://www.fda.gov/cdrh/dsmamain.html.

Sincerely yours,

Celia M. Witten, Ph.D., M.D. Director Division of General and Restorative Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{3}------------------------------------------------

(Optimal Formate 1-2-96)

ITEM 1J: INDICATIONS FOR USE STATEMENT

1972530 510(k) Number (if known): Not Known

Device Name: ConvaTec Odor Control Wound Dressing

Indications for Use:

ConvaTec Odor Control Wound Dressing is indicated for the management of malodorous acute and chronic wounds such as pressure ulcers, leg ulcers, and diabetic ulcers. It may be used as a primary dressing for superficial wounds or with deeper wounds as a secondary dressing.

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

(Division Sign-Off)
Division of General Restorative Devices

510(k) NumberK972530
------------------------
Prescription UseOver-the-Counter Use
------------------------------------------------------

(Per 21 CFR 801.109)

§ 880.5090 Liquid bandage.

(a)
Identification. A liquid bandage is a sterile device that is a liquid, semiliquid, or powder and liquid combination used to cover an opening in the skin or as a dressing for burns. The device is also used as a topical skin protectant.(b)
Classification. Class I (general controls). When used only as a skin protectant, the device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 880.9.